Thesis

General introduction and thesis outline 33 1 carcinogenesis: concepts and clinical implications. J Pathol 2006; 208(2): 152-64. 56. Sen P, Ganguly P, Ganguly N. Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer. Oncol Lett 2018; 15(1): 11-22. 57. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10(8): 550-60. 58. Klingelhutz AJ, Roman A. Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Virology 2012; 424(2): 77-98. 59. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; (2): 213-28. 60. McLaughlin-Drubin ME, Munger K. Biochemical and functional interactions of human papillomavirus proteins with polycomb group proteins. Viruses 2013; (5): 1231-49. 61. Silva DC, Gonçalves AK, Cobucci RN, Mendonça RC, Lima PH, Cavalcanti GJ. Immunohistochemical expression of p16, Ki-67 and p53 in cervical lesions - A systematic review. Pathol Res Pract 2017; (7): 723-9. 62. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007; (4): 297-313. 63. Koeneman MM, Kruitwagen RF, Nijman HW, Slangen BF, Van Gorp T, Kruse AJ. Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers. Expert Rev Mol Diagn 2015; (4): 527-46. 64. Wright TC, Jr., Stoler MH, Ferenczy A, Ranger-Moore J, Fang Q, Kapadia M, et al. The CERTAIN Study Results: Adjunctive p16 Immunohistochemistry Use in Cervical Biopsies According to LAST Criteria. Am J Surg Pathol 2021; (10): 1348-56. 65. Korzeniewski N, Spardy N, Duensing A, Duensing S. Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett 2011; (2): 113-22. 66. Wilting SM, Steenbergen RDM. Molecular events leading to HPV-induced high grade neoplasia. Papillomavirus Res 2016; : 85-8. 67. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. https://www.who. int/publications/i/item/9789240014107 (accessed 03-03-2023. 68. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirusassociated malignancies. Expert Rev Vaccines 2013; 12(2): 129-41. 69. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367(9518): 1247-55. 70. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686): 301-14. 71. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356(19): 1928-43. 72. Group FIS. Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N Engl J Med 2007; 356(19): 1915-27. 73. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and

RkJQdWJsaXNoZXIy MjY0ODMw